The effects of 24 weeks' treatment with an angiotensin 2 receptor blocker (ARB)/diuretic combination drug were investigated in an open-label study of 61 patients with stabilized chronic heart failure. Renin—angiotensin—aldosterone system inhibitors were replaced with a tablet containing hydrochlorothiazide 6.25 mg plus candesartan 8 mg, administered orally, once daily, in patients with systolic blood pressure (SBP) ≥ 140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg while under optimal treatment. Both SBP and DBP declined significantly during the ARB/diuretic combination treatment. Diuretics administered previously were discontinued during the study period in 15 patients, decreasing the number of drugs being taken. During ARB/diuretic combination treatment, the blood urea nitrogen level worsened but no significant changes were noted in potassium or estimated glomerular filtration rate, which had been a matter of concern. Additionally, the level of brain natriuretic peptide, an indicator of the severity of heart failure, was improved, indicating effectiveness and safety of the ARB/diuretic combination drug.
WattsJAMarchickMRKlineJA: Right ventricular heart failure from pulmonary embolism: key distinctions from chronic pulmonary hypertension. J Card Fail2010; 16: 250–259.
2.
FrazierLWungSFSparksE: Cardiovascular nursing on human genomics: what do cardiovascular nurses need to know about congestive heart failure?Prog Cardiovasc Nurs2009; 24: 80–85.
3.
BogaardHJAbeKVonk NoordegraafA: The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest2009; 135: 794–804.
4.
LevyDLarsonMGVasanRS: The progression from hypertension to congestive heart failure. JAMA1996; 275: 1557–1562.
5.
HeJOgdenLGBazzanoLA: Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med2001; 161: 996–1002.
6.
DevereuxRBDahlofBGerdtsE: Regression of hypertensive left ventricular hypertension by losartan compared with atenolol: the Losartan Intervention for Reduction in Hypertension (LIFE) trial. Circulation2004; 110: 1456–1462.
7.
DavisBRPillerLBCutlerJA: Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation2006; 113: 2201–2210.
8.
CruickshankJM: Beta-blockers and heart failure. Indian Heart J2010; 62: 101–110.
9.
JentzerJCDeWaldTAHernandezAF: Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol2010; 56: 1527–1534.
10.
McGavinJKKeatingGM: Bisprolol: A review of its use in chronic heart failure. Drugs2002; 62: 2677–2696.
11.
RavandiATeoKK: Blocking the renin—angiotensin system: dual- versus mono-therapy. Expert Rev Cardiovasc Ther2009; 7: 667–674.
12.
AronowWS: Management of atrial fibrillation in the elderly. Minerva Med2009; 100: 3–24.
13.
AronowWS: Management of atrial fibrillation—Part 1. Compr Ther2008; 34: 126–133.
14.
Tsuchihashi-MakayaMHamaguchiSKinugawaS: Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J2009; 73: 1893–1900.
15.
VerdecchiaPAngeliFCavalliniC: Blood pressure reduction and renin—angiotensin system inhibition for prevention of congestive heart failure: A meta-analysis. Eur Heart J2009; 30: 679–688.
16.
TanFMukherjeeJJLeeKO: Dual blockade of the renin—angiotensin—aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy. Singapore Med J2010; 51: 151–156.
17.
SpinarJVítovecJSoučekM: CORD: COmparison of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers. Int J Cardiol2010; 144: 293–294.
18.
JentzerJCDeWaldTAHernandezAF: Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol2010; 56: 1527–1534.
19.
LiszkowskiMNohriaA: Rubbing salt into wounds: hypertonic saline to assist with volume removal in heart failure. Curr Heart Fail Rep2010; 7: 134–139.
20.
PittBZannadFRemmeWJ: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med1999; 341: 709–717.
21.
PittD: ACE inhibitor co-therapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). Eur Heart J1995; 16 (suppl N): 107–110.
22.
UzuTKimuraG: Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation1999; 100: 1635–1638.
23.
ShargorodskyMBoazMDavidovitzI: Treatment of hypertension with thiazides: benefit or damage-effect of low- and high-dose thiazide diuretics on arterial elasticity and metabolic parameters in hypertensive patients with and without glucose intolerance: J Cardiometab Syndr2007, 2: 16–23.
24.
SchmiederRE: The role of fixed-dose combination therapy with drugs that target the renin—angiotensin system in the hypertension paradigm. Clin Exp Hypertens2010; 32: 35–42.
25.
KondrackRMohiuddinS: Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy. Expert Opin Drug Metab Toxicol2009; 5: 1125–1134.
26.
PasqualePDSarulloFMPaternaS: Novel strategies: challenge loop diuretics and sodium management in heart failure—Part I. Congest Heart Fail2007; 13: 93–98.
27.
FerrarioCMSmithRD: Role of olmesartan in combination therapy in blood pressure control and vascular function. Vasc Health Risk Manag2010; 6: 701–709.
28.
SchernthanerG: Fixed-dose combination therapies in the management of hyperglycaemia in type 2 diabetes: an opportunity to improve adherence and patient care. Diabet Med2010; 27: 739–743.
29.
BaserOAndrewsLMWangL: Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy. J Med Econ2011; epub ahead of print.
30.
GuptaAKArshadSPoulterNR: Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysis. Hypertension2010; 55: 399–407.
31.
LindholmLHAndersonHEkbomT: Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: A 5-year, prospective, randomised, controlled trial. Lancet2001; 358: 539–544.
32.
HaywoodLJFordCECrowRS, ALLHAT Collaborative Research Group: Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol2009; 54: 2023–2031.
33.
WachtellKPalmieriVGerdtsE: Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study). Am J Cardiol2010; 106: 999–1005.
34.
RuilopeLMPalmerCRBrownMJ: Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med2004; 164: 2459–2464.
35.
YusufSPfefferMASwedbergK: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet2003; 362: 777–781.
36.
MatsumoriA: Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) study investigators. Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail2003; 5: 669–677.
